Latest Earnings Results: Q3 '26
Estimated EPS
-$0.93
Reported EPS
-$1.08
Surprise
-16.24%
Estimated Rev
$8.21M
Reported Rev
$11.26M
Surprise
+37.06%
• Reported GAAP EPS of -$1.08 down -66.15% YoY • Reported revenue of $11.26M up 5.93% YoY • Stoke Therapeutics said its $358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 is expected to fund operations into early 2028.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$1.15 | -- | -- | N/A |
Q3 '26 | -$0.93 | -$1.08 | -16.24% | MISSED |
Q2 '26 | -$0.80 | -$0.93 | -16.98% | MISSED |
Q1 '26 | -$0.81 | -$0.79 | 2.17% | BEAT |
Q4 '25 | -$0.93 | -- | -- | N/A |